BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31192214)

  • 1. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
    Oka T; Miyagaki T
    Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
    Chung CG; Poligone B
    Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.
    Giordano A; Pagano L
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022029. PubMed ID: 35444765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
    Prince HM; Querfeld C
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
    Photiou L; van der Weyden C; McCormack C; Miles Prince H
    Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
    Xu S; Foss F
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides and Sézary syndrome.
    Lee H
    Blood Res; 2023 Apr; 58(S1):66-82. PubMed ID: 37105561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Targeted Treatments for Cutaneous T-cell Lymphomas.
    Bagot M
    Indian J Dermatol; 2017; 62(2):142-145. PubMed ID: 28400633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat mycosis fungoides and Sézary syndrome.
    Whittaker S; Hoppe R; Prince HM
    Blood; 2016 Jun; 127(25):3142-53. PubMed ID: 27151889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.
    Miyashiro D; Sanches JA
    Front Oncol; 2023; 13():1141108. PubMed ID: 37124514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat mycosis fungoides and Sézary syndrome.
    Prince HM; Whittaker S; Hoppe RT
    Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
    Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
    PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycosis fungoides and sezary syndrome: an update.
    Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
    Mehta-Shah N; Horwitz SM; Ansell S; Ai WZ; Barnes J; Barta SK; Clemens MW; Dogan A; Fisher K; Goodman AM; Goyal G; Guitart J; Halwani A; Haverkos BM; Hoppe RT; Jacobsen E; Jagadeesh D; Lunning MA; Mehta A; Olsen EA; Pro B; Rajguru SA; Shanbhag S; Shaver A; Shustov A; Sokol L; Torka P; Torres-Cabala C; Wilcox R; William BM; Zain J; Dwyer MA; Sundar H; Kim YH
    J Natl Compr Canc Netw; 2020 May; 18(5):522-536. PubMed ID: 32380458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.